Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
Anna M. Sawka(University of Toronto), Charles H. Goldsmith(Impact), Robert G. Josse(Western University), Lehana Thabane(Impact), K. Shawn Davison(University of Victoria), Jacques P. Brown(Centre hospitalier de l'Université Laval), Rolf J. Sebaldt(Murdoch Children's Research Institute), George Ioannidis(McMaster University Medical Centre), Αλεξάνδρα Παπαϊωάννου(Western University), Jonathan D. Adachi(St. Peter's Hospital), Alan Tenenhouse(St. Vincent's Birmingham), Tim Murray, Annie Petrie(McMaster University), David A. Hanley(The University of Sydney), Wojciech P. Olszynski(University of Saskatchewan)
PubMed
October 1, 2004
Cited by 13
Related Papers
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
|Pilot and Feasibility Studies|2016|3k
Body mass index as a predictor of fracture risk: A meta-analysis
|Osteoporosis International|2005|1.6k